Adial Pharmaceuticals

There is no demonstrated pricing power today. If approved, AD04 would compete with generics such as naltrexone and acamprosate and EU precedent with nalmefene shows harm‑reduction agents can be reimbursed but often at moderate prices. The company’s own materials modeled relatively modest monthly pricing.

AT177, if it shows best‑in‑class efficacy with improved safety, could command specialty pricing in UC, but the class is crowded and payer step‑edits are common. With no revenues and no Phase 3 data yet for AT177, latent pricing power remains speculative.

Score reflects the possibility of pricing leverage if either asset crosses the approval bar and is clinically differentiated. (ema.europa.eu).